MAIN CONTENT
A near 47 per cent drop in one session
Tuesday’s trading session was a grim day for ArriVent BioPharma. The company’s shares closed down almost 47 per cent after it announced that firmonertinib had missed its primary goal in a phase 3 trial. The drug failed to show that it could significantly delay disease progression compared with standard chemotherapy, the key measure needed to persuade regulators.
Chairman and chief executive Bing Yao acknowledged that the results were disappointing and fell short of expectations. He said the company was analysing the full trial data to decide the most suitable development path for the drug. In 2021, ArriVent acquired exclusive rights to develop and commercialise firmonertinib outside China, becoming one of the first US biotech firms to bet on a Chinese drug asset.
Success in second line, a stumble in first line
Firmonertinib targets non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, a patient group with few treatment options. According to Tony Ren, head of Asia healthcare research at Macquarie Capital, the drug was approved in China in February as a second-line treatment, whereas ArriVent’s trial assessed it as a first-line therapy.
















